Is CELC a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on REVTORPYK launch execution, with revenue (ttm) at ~$0 (launched September 30, 2026); 2026 consensus ~$23M. The bear case rests on celcuity is still essentially a single-product company, so a slow launch, a delay or narrow outcome on the PIK3CA-mutant sNDA, or disappointing later cohort data could sharply reduce the value the market assigns. Analysts covering it are spread from $130.00 to $177.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Celcuity is still essentially a single-product company, so a slow launch, a delay or narrow outcome on the PIK3CA-mutant sNDA, or disappointing later cohort data could sharply reduce the value the market assigns. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $130.00, +129.8% from the $56.58 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

REVTORPYK launch execution. The FDA approval on July 14, 2026 converted Celcuity from a pre-revenue developer into a commercial-stage company, and the drug became commercially available in the US on September 30, 2026. The most optimistic analyst target on CELC is $177.00, +212.8% from the $56.58 price. That figure is only reachable if this thesis works close to its best case.

Celcuity is still essentially a single-product company, so a slow launch, a delay or narrow outcome on the PIK3CA-mutant sNDA, or disappointing later cohort data could sharply reduce the value the market assigns. The stock fell about 31% in the month to October 16, 2026 and about 17% in the week around the launch and sNDA news, which shows how harshly it is being judged on early commercial signals. It lost about $226 million over the trailing twelve months and spending is rising with the launch. The June 2026 convertible offering removed near-term funding pressure (about $754 million of cash, a runway management puts into 2029), but it also added about $575 million of convertible debt that can dilute holders if converted at about $124.53 a share. Commercial uptake faces entrenched and newly approved competitors, payer and pricing pressure, and the operational challenge of a first launch. The stock has been volatile and can gap on single events, which is characteristic of small biotech rather than a defect specific to this name. The most pessimistic published target is $130.00, +129.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (REVTORPYK launch execution) stalling in the reported numbers rather than in the narrative, the risk above (celcuity is still essentially a single-product company, so a slow launch, a delay or narrow outcome on the PIK3CA-mutant sNDA, or disappointing later cohort data could sharply reduce the value the market assigns) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Celcuity is a biotechnology company developing and now selling targeted cancer therapies. Its lead drug, gedatolisib, is a pan-PI3K/AKT/mTOR inhibitor approved in July 2026 as REVTORPYK for a subset of HR+/HER2- advanced breast cancer, and the company also runs diagnostic and functional-testing work supporting its programs.

Not yet in meaningful amounts. REVTORPYK became commercially available in the US on September 30, 2026, so reported revenue through June 2026 was zero, and the second quarter net loss was about $78.9 million. Consensus expects about $22.8 million of revenue for 2026 and about $324 million for 2027.

Gedatolisib, sold as REVTORPYK, is Celcuity's lead drug, an intravenously administered inhibitor that blocks all four class I PI3K isoforms plus mTORC1 and mTORC2. The design aims to suppress the whole pathway at once and reduce the adaptive resistance that single-target drugs can trigger.